IP Library Granted Patent US 8,124,382
Granted Patent B2
US 8,124,382 · App. 12/097,237 · Granted Feb 28, 2012

Methods, microarray, and kits for detection of drug resistance genes in gram-negative bacteria

Assignees: CapitalBio Corporation; Tsinghua University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,382
App. No.
12/097,237
Granted
Feb 28, 2012
Kind
B2
Abstract

The present invention provides kits and microarrays containing primer pairs for amplifying drug resistance genes and/or probes for detection of drug resistance genes. Also provided are methods of detecting drug resistance genes using kits and microarrays described herein.

Claims (18)

1. A kit for detecting one or more drug resistance genes in a gram-negative bacteria, comprising at least five primer pairs selected from the group consisting of SEQ ID NOS: 2 and 3, SEQ ID NOS: 4 and 5, SEQ ID NOS: 6 and 7, SEQ ID NOS: 8 and 9, SEQ ID NOS: 10 and 11, SEQ ID NOS: 12-13, SEQ ID NOS: 14-15, SEQ ID NOS: 16-17, SEQ ID NOS: 18-19or SEQ ID NOS: 20-21 primer pairs for amplification of a drug resistance gene, wherein the drug resistance gene is selected from the group consisting of tem, shv, ctx-m-1-type, ctx-m-9-type, mox, cit, dha, acc, ebc, and fox.

2. The kit of claim 1 , wherein the gram-negative bacteria is selected from the group consisting of E. coli, K pneumoniae , and E. cloacae.

3. The kit of claim 1 , wherein the kit further comprises one or more probes for detecting at least one drug resistance gene selected from the group consisting of tem, shv, ctx-m-1-type, ctx-m-9-type, mox, cit, dha, acc, ebc, and fox.

4. The kit of claim 3 , wherein the kit comprises at least two probes having the sequence as set forth in SEQ ID NOS:22-52.

5. The kit of claim 4 , wherein the kit comprises at least five probes having the sequence as set forth in SEQ ID NOS:22-52.

6. The kit of claim 3 , further comprising one or more control probes, wherein the control probe is selected from the group consisting of: surface chemistry control probe, hybridization control probe, and negative control probe.

7. The kit of claim 3 , wherein the probes are immobilized on a carrier.

8. The kit of claim 1 , further comprising solutions for PCR reaction or solution for hybridization reaction.

9. The kit of claim 1 , further comprising an instruction for using the kit.

10. A microarray for detection of a drug resistance gene in gram-negative bacteria, comprising at least one probe for a gene selected from the group consisting of tem, shv, ctx-m-1-type, ctx-m-9-type, mox, cit, dha, acc, ebc, and fox, wherein the microarray comprises at least two probes having the sequence as set forth in SEQ ID NOS:22-52.

11. The microarray of claim 10 , wherein the microarray comprises at least five probes having the sequence as set forth in SEQ ID NOS:22-52.

12. The microarray of claim 10 , further comprising one or more control probes, wherein the control probe is selected from the group consisting of: surface chemistry control probe, hybridization control probe, negative control probe.

13. The microarray of claim 12 , wherein the probes are about 15-35 nucleotides.

14. A method for detecting a drug resistance gene in gram-negative bacteria comprising: a) performing PCR using at least one primer pair that amplify a drug resistance gene of gram-negative bacteria; and b) hybridizing the amplified products with at least two probes having the sequence as set forth in SEQ ID NOS:22-52 to detect the drug resistance gene, wherein the drug resistance gene is selected from the group consisting of tem, shv, ctx-m-1-type, ctx-m-9-type, mox, cit, dha, acc, ebc, and fox.

15. The method of claim 14 , wherein the PCR is multiplex asymmetric PCR.

16. The method of claim 14 , wherein the concentration of the two primers in each pair are equal.

17. The method of claim 16 , wherein one of the primers in each pair comprises a universal tag sequence at the 5′ end, and wherein the concentration of the tagged primer is about 5-100 folds of that of the untagged primer.

18. The method of claim 17 , wherein the PCR comprises 10-25 cycles of denaturation, annealing, and extension, followed by 10-25 cycles of denaturation and extension.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2011
From: CAPITALBIO CORPORATION
To: CAPITALBIO CORPORATION; TSINGHUA UNIVERSTIY
Reel/Frame 026093/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2008
From: ZHU, LINGXIANG; ZHANG, ZHIWEI; JIANG, DI; DU, NING; WANG, CAN; YANG, HUAWEI; ZHANG, QIONG; GAO, HUAFANG; ZHOU, YUXIANG; CHENG, JING
To: CAPITALBIO CORPORATION
Reel/Frame 021878/0007 →
Priority Claims (1)
CN 2006 1 0001309 · Jan 18, 2006 · national
Continuity (1)
Related Publication 20090239758A1 · Sep 24, 2009